Palatin Technologies presented new preclinical data at ObesityWeek 2026, showcasing its MC4R-selective peptide agonists. The lead candidate, PL2001, demonstrated significant weight-loss efficacy in animal models and a half-life exceeding 168 hours in dogs. The company plans to initiate first-in-human studies for PL2001 in the first half of 2027, with initial clinical data expected in the second half of 2027.
The company presents preclinical data showing greater than 100-fold to greater than 200-fold MC4R selectivity, weight-loss efficacy in obese mice, and half-lives of roughly 24 hours in rodents and greater than 168 hours in dogs, with PL2001 selected for first-in-human studies in the first half of 2027. These are supportive pipeline milestones that may lift sentiment, but they are animal and in vitro results without a comparable prior figure being beaten, so no hard fact changes the financial outlook. Clinical data is not expected until the second half of 2027.
- • Poster presentation at ObesityWeek 2026 on November 14, 2026
- • PL2001 selected as clinical development candidate with first-in-human studies targeted for the first half of 2027
- • All reported data are preclinical (in vitro and animal models) and may not translate to humans
- • Initial clinical data not anticipated until the second half of 2027